The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SCREENING
Masking
DOUBLE
Enrollment
1,400
Administered orally
Administered orally
Clinical Research Institute of Arizona (CRI) - Sun City West
Sun City West, Arizona, United States
Novak Clinical Research - Tucson - North La Cholla Boulevard
Tucson, Arizona, United States
Norcal Endocrinology & Internal Medicine
San Ramon, California, United States
Southern California Clinical Research
Santa Ana, California, United States
Care Access - Thousand Oaks
Thousand Oaks, California, United States
Number of Participants Allocated to Each Study
Time frame: Baseline to Week 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Accel Research Sites - DeLand Clinical Research Unit
DeLand, Florida, United States
Innovation Medical Research Center - Fort Lauderdale
Fort Lauderdale, Florida, United States
Indago Research & Health Center, Inc
Hialeah, Florida, United States
Encore Medical Research
Hollywood, Florida, United States
West Orange Endocrinology P.A.
Ocoee, Florida, United States
...and 70 more locations